References
- Bölcskei É, Regdon Jr G, Sovány T, et al. Optimization of preparation of matrix pellets containing Eudragit® NE 30D. Chem Eng Res Des 2012;90:651–7
- Ghanam D, Kleinebudde P. Suitability of a flat die press for the manufacture of pharmaceutical pellets by extrusion/spheronization. Drug Dev Ind Pharm 2011;37:456–64
- O’Connor R, Schwartz JB. Spheronization II: drug release from drug–diluents mixtures. Drug Dev Ind Pharm 1985;11:1837–57
- Basit AW, Newton JM, Lacey LF. Formulation of ranitidine pellets by extrusion-spheronization with little or no microcrystalline cellulose. Pharm Dev Technol 1999;4:499–505
- Okada T, Nakahara H, Isaka H. Adsorption of drugs and microcrystalline cellulose suspended in aqueous solutions. Chem Pharm Bull 1987;35:761–8
- El-Malah Y, Nazzal S. Novel use of Eudragit® NE 30D/Eudragit® L 30D-55 blends as functional coating materials in time-delayed drug release applications. Int J Pharm 2008;357:219–27
- American Pharmaceutical Association and the Pharmaceutical Society of G.B. Production. Handbook of pharmaceutical excipients. Washington, DC: The Pharmaceutical Press; 1986
- Krajacic A, Tucke IG. Matrix formation in sustained release tablets: possible mechanism of dose dumping. Int J Pharm 2003;251:67–78
- Eudragit® Brochure. Darmstadt: Röhm GmbH & Co. KG, Pharma Polymers; 2005
- Salako M, Podczeck F, Newton JM. Investigations into the deformability and tensile strength of pellets. Int J Pharm 1998;168:49–57
- Hamedelniel EI, Bajdik J, Pintye-Hódi K. Optimization of preparation of matrix pellets containing ethylcellulose. Chem Eng Process 2010;49:120–4